Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program

Table 3 Results from base-case analysis

Outcome measure	RI-HSCT	BT-ICT	RI-HSCT vs BT-ICT
Costs*
Direct Medical Cost	83,733.58	28,651.11	55,082.47
Direct Non Medical Cost	9,877.00	29,928.83	−20,541.83
Indirect Cost	20,389.58	15,347.89	5,041.69
Total	114,000.16	73,927.83	40,072.33
QALYs	26.50	14.11	12.38
Cost per QALY gained			3,236.37

QALY = Quality adjusted life year; RI-HSCT: Reduced intensity hematopoietic stem cell; BT-ICT: Blood transfusion combined with subcutaneous iron chelating therapy.
* ($US, year 2011 value).

ISSN: 1472-6963